HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry - A study of interlaboratory agreement

被引:93
作者
Jacobs, TW
Gown, AM
Yaziji, H
Barnes, MJ
Schnitt, SJ
机构
[1] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA
[2] PhenoPath Labs, Seattle, WA USA
[3] IRIS, Seattle, WA USA
关键词
immunohistochemistry; HER-2/neu; c-erbB-2; breast cancer;
D O I
10.1309/980M-E24R-V19K-595D
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Immunohistochemistry (IHC) is used commonly for evaluating HER-2/neu protein expression in breast cancer. Given the potential clinical importance of HER-2/neu status in patient management, interlaboratory variability in HER-2/neu IHC results is a matter of legitimate concern. We compared the results from 2 laboratories for HER-2/neu determined by IHC on paraffin sections of the same 100 consecutive invasive breast cancers. Both laboratories used the same primary antibody; however, different methods for heat-induced epitope retrieval (microwave or steam) and immunostaining (automated equipment from different manufacturers) and different scoring systems (positive-negative and 0-4+) were used. Slides were read in a blinded fashion and the results from the 2 laboratories were compared. Of the 93 cases evaluable in both laboratories, 24% were scored as HER-2/neu-positive at 1 laboratory, and 23% were scored as positive at the other. Complete concordance in categorization of HER-2/neu status between the 2 laboratories was achieved in 90 of 93 cases. Excellent interlaboratory agreement for HER-2/new IHC was attained suing the same primary antibody to HER-2/new, even without standardization of assay method or scoring criteria. However, standardization of these parameters remains an important objective to optimize interlaboratory agreement.
引用
收藏
页码:251 / 258
页数:8
相关论文
共 74 条
[1]  
Albanell J, 1996, ANTICANCER RES, V16, P1027
[2]   HER-2/NEU IN NODE-NEGATIVE BREAST-CANCER - PROGNOSTIC-SIGNIFICANCE OF OVEREXPRESSION INFLUENCED BY THE PRESENCE OF INSITU CARCINOMA [J].
ALLRED, DC ;
CLARK, GM ;
TANDON, AK ;
MOLINA, R ;
TORMEY, DC ;
OSBORNE, CK ;
GILCHRIST, KW ;
MANSOUR, EG ;
ABELOFF, M ;
EUDEY, L ;
MCGUIRE, WL .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (04) :599-605
[3]   ASSOCIATION OF C-ERBB-2 EXPRESSION AND S-PHASE FRACTION IN THE PROGNOSIS OF NODE POSITIVE BREAST-CANCER [J].
ANBAZHAGAN, R ;
GELBER, RD ;
BETTELHEIM, R ;
GOLDHIRSCH, A ;
GUSTERSON, BA .
ANNALS OF ONCOLOGY, 1991, 2 (01) :47-53
[4]   neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer [J].
Andrulis, IL ;
Bull, SB ;
Blackstein, ME ;
Sutherland, D ;
Mak, C ;
Sidlofsky, S ;
Pritzker, KPH ;
Hartwick, RW ;
Hanna, W ;
Lickley, L ;
Wilkinson, R ;
Qizilbash, A ;
Ambus, U ;
Lipa, M ;
Weizel, H ;
Katz, A ;
Baida, M ;
Mariz, S ;
Stoik, G ;
Dacamara, P ;
Strongitharm, D ;
Geddie, W ;
McCready, D .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1340-1349
[5]   PROGNOSTIC-SIGNIFICANCE OF C-ERBB-2 EXPRESSION IN NODE NEGATIVE BREAST-CANCER [J].
BIANCHI, S ;
PAGLIERANI, M ;
ZAMPI, G ;
CARDONA, G ;
CATALIOTTI, L ;
BONARDI, R ;
CIATTO, S .
BRITISH JOURNAL OF CANCER, 1993, 67 (03) :625-629
[6]  
Bitran JD, 1996, CLIN CANCER RES, V2, P1509
[7]  
Bobrow LG, 1996, APPL IMMUNOHISTOCHEM, V4, P128
[8]   ERBB2 AMPLIFICATION IS ASSOCIATED WITH TAMOXIFEN RESISTANCE IN STEROID-RECEPTOR POSITIVE BREAST-CANCER [J].
BORG, A ;
BALDETORP, B ;
FERNO, M ;
KILLANDER, D ;
OLSSON, H ;
RYDEN, S ;
SIGURDSSON, H .
CANCER LETTERS, 1994, 81 (02) :137-144
[9]  
BORG A, 1990, CANCER RES, V50, P4332
[10]   ANALYSIS OF CERBB2 EXPRESSION USING A PANEL OF 6 COMMERCIALLY AVAILABLE ANTIBODIES [J].
BUSMANIS, I ;
FELEPPA, F ;
JONES, A ;
MCGRATH, KM ;
REED, R ;
COLLINS, J ;
RUSSELL, I ;
BEGLEY, CG .
PATHOLOGY, 1994, 26 (03) :261-267